Literature DB >> 20675683

Diagnostic accuracy: theoretical models for preimplantation genetic testing of a single nucleus using the fluorescence in situ hybridization technique.

P N Scriven1, P M M Bossuyt.   

Abstract

BACKGROUND: The aim of this study was to develop and use theoretical models to investigate the accuracy of the fluorescence in situ hybridization (FISH) technique in testing a single nucleus from a preimplantation embryo without the complicating effect of mosaicism.
METHODS: Mathematical models were constructed for three different applications of FISH in preimplantation genetic testing (sex determination for sex-linked diseases, two-way reciprocal translocations and sporadic chromosome aneuploidy). The input values were the degree of aneuploidy (initially set at 3% per chromosome for sporadic aneuploidy) and the accuracy per probe (initially set at 95%), defined as the proportion of normal diploid nuclei with a normal signal pattern. The primary statistic was the predictive value of the test result.
RESULTS: Testing two chromosome pairs to determine sex chromosome status or detect unbalanced translocation products had high predictive value: at least 99.5% for a normal test result (95% CI: 99-100%), and 90% for an abnormal test result (95% CI: 88-92%). However, the predictive value of an abnormal test result testing five chromosomes for sporadic chromosome aneuploidy was 41% (95% CI: 36-46%); 90% would be achieved with an aneuploidy rate per chromosome of 20.3% (equivalent to 99.5% prevalence for 23 chromosomes) rather than 3%, or with an accuracy per probe of 99.6% rather than 95%, or when testing 23 chromosome pairs, rather than 5 pairs, with either 8.3% aneuploidy (86.4% prevalence) or 99.5% accuracy.
CONCLUSIONS: Testing a single cell using the FISH technique has the potential to achieve acceptable analytical performance for sex determination and two-way reciprocal translocations, but is unlikely to achieve adequate performance testing for sporadic chromosome aneuploidy. New techniques for detecting the copy number of every chromosome are emerging, but it remains to be seen if the high accuracy required will be achieved.

Entities:  

Mesh:

Year:  2010        PMID: 20675683     DOI: 10.1093/humrep/deq196

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  8 in total

1.  Singling out genetic disorders and disease.

Authors:  Martine De Rycke
Journal:  Genome Med       Date:  2010-10-06       Impact factor: 11.117

2.  Meiotic outcomes of three-way translocations ascertained in cleavage-stage embryos: refinement of reproductive risks and implications for PGD.

Authors:  Paul N Scriven; Susan M Bint; Angela F Davies; Caroline Mackie Ogilvie
Journal:  Eur J Hum Genet       Date:  2013-10-16       Impact factor: 4.246

3.  A tale of two studies: now is no longer the best of times for preimplantation genetic testing for aneuploidy (PGT-A).

Authors:  Paul N Scriven
Journal:  J Assist Reprod Genet       Date:  2020-02-05       Impact factor: 3.412

4.  FISH for pre-implantation genetic diagnosis.

Authors:  Paul N Scriven; Toby L Kirby; Caroline Mackie Ogilvie
Journal:  J Vis Exp       Date:  2011-02-23       Impact factor: 1.355

5.  Combining PGT-A with PGT-M risks trying to do too much.

Authors:  Paul N Scriven
Journal:  J Assist Reprod Genet       Date:  2022-05-18       Impact factor: 3.357

Review 6.  Detecting mosaicism in trophectoderm biopsies: current challenges and future possibilities.

Authors:  Antonio Capalbo; Filippo Maria Ubaldi; Laura Rienzi; Richard Scott; Nathan Treff
Journal:  Hum Reprod       Date:  2017-03-01       Impact factor: 6.918

Review 7.  Preimplantation chromosomal mosaics, chimaeras and confined placental mosaicism.

Authors:  John D West; Clare A Everett
Journal:  Reprod Fertil       Date:  2022-04-05

8.  Preimplantation genetic testing for aneuploidies (abnormal number of chromosomes) in in vitro fertilisation.

Authors:  Simone Cornelisse; Miriam Zagers; Elena Kostova; Kathrin Fleischer; Madelon van Wely; Sebastiaan Mastenbroek
Journal:  Cochrane Database Syst Rev       Date:  2020-09-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.